카지노 슬롯머신 규칙

In the post-COVID landscape, South Korean branches of multinational pharmaceutical companies experienced notable revenue declines—particularly those that previously benefited from vaccine sales. Yet amid the downturn, AstraZeneca Korea posted record earnings, topping peers in both operating and net income.

According to Hit News' analysis of financial audit reports filed with the Financial Supervisory Service by April 15, key vaccine suppliers—Pfizer Korea, MSD Korea, AstraZeneca Korea, and Moderna Korea—recorded significant year-over-year revenue drops in 2023.

Pfizer maintained 카지노 슬롯머신 규칙 top-line position with .13 billion in sales. However, revenue dropped 51.1% year-over-year to 2 million. Operating and net prof카지노 슬롯머신 규칙 also declined by 57.4% and 58.0%, respectively. As the first to launch a COVID-19 vaccine in Korea, Pfizer's initial dominance gave way to flat growth in 카지노 슬롯머신 규칙 broader portfolio.

MSD Korea saw 카지노 슬롯머신 규칙 revenue fall 12.2%, from 6 million to 0 million. Still, growth in 카지노 슬롯머신 규칙 oncology drug Keytruda (pembrolizumab) and the inclusion of Vaxneuvance—카지노 슬롯머신 규칙 15-valent pneumococcal conjugate vaccine—in the National Immunization Program helped offset losses. Operating profit declined 9.3%, while net profit rose 13.8%.

In contrast, AstraZeneca Korea limited 카지노 슬롯머신 규칙 revenue decline to just 5.7%, largely due to 카지노 슬롯머신 규칙 early exit from the vaccine market. Operating profit soared 988.8% to .1 million, while net profit jumped 1314.5% to .4 million—the highest growth among 카지노 슬롯머신 규칙 peers.

Despite pulling Farxiga (dapagliflozin) from the market in Q2 2023, AstraZeneca continued sales of 카지노 슬롯머신 규칙 combination products—Xigduo, Qtern, and Sidapvia. While Farxiga’s removal was expected to reduce earnings, strong uptake of Tagrisso (osimertinib) more than compensated. Approved in January 2023 for first-line treatment of EGFR-mutated non-small cell lung cancer, Tagrisso’s outpatient prescriptions surged 53.4% to .8 million, according to Ubist.

Novo Nordisk Korea also reported strong gains, driven by the launch of Wegovy (semaglutide), a once-weekly GLP-1 receptor agonist for obesity. Using 카지노 슬롯머신 규칙 existing Saxenda sales network, the company rapidly penetrated the market despite temporary shortages fueled by social media demand.

Amgen Korea followed with robust performance, generating 3 million in sales for 카지노 슬롯머신 규칙 osteoporosis treatment Prolia (denosumab), representing over 60% of 카지노 슬롯머신 규칙 total 0 million revenue, per IQVIA.

However, Prolia’s dominance may wane. With the April 1 reimbursement listing of Celltrion’s biosimilars—Stoboclo and Osenvelt—a mandated price cut reduced Prolia’s ceiling price to 80% of 카지노 슬롯머신 규칙 original.

In contrast, some companies struggled. Kyowa Kirin Korea offloaded 카지노 슬롯머신 규칙 hematology and nephrology portfolio to DKSH Korea in late 2023 and downsized operations, retaining only 카지노 슬롯머신 규칙 rare disease unit. The company implemented an early retirement program for the remainder of 카지노 슬롯머신 규칙 workforce.

Looking ahead, ongoing uncertainties—such as Korea’s healthcare worker strike and looming international price reviews—are expected to influence how global pharma companies recalibrate their Asia-Pacific strategies, particularly within the Korean market.